Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chronic Pain Indications Will Be Harder To Come By, FDA Says

Executive Summary

A general chronic pain indication may elude Eli Lilly's Cymbalta near the finish line because FDA has changed its thinking about the evidence needed to support the claim
Advertisement

Related Content

Cymbalta Adds Musculoskeletal Pain Claim Despite Advisory Committee Concerns
Cymbalta Chronic Pain Label: FDA Expresses Faith In Physicians' Judgment
Cymbalta Could Get "Fairly Narrow Broad Indication" For Pain, FDA's Rappaport Says
Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later
Advanced Life Sciences Restanza Blocked By New FDA Efficacy Criteria
Diabetes Drug Developers Urged To Study Higher Risk Patients By FDA Panel
FDA’s Diabetes Guidance On CV Risk Will Get First Test With Pending NDAs
FDA’s Diabetes Guidance On CV Risk Will Get First Test With Pending NDAs

Topics

Advertisement
UsernamePublicRestriction

Register

PS052558

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel